Imvexxy Shortage: What Providers and Prescribers Need to Know in 2026

Providers who prescribe Imvexxy (estradiol vaginal inserts) for menopausal vulvar and vaginal atrophy are hearing from patients who cannot fill their prescriptions. While Imvexxy is not on the FDA's official Drug Shortage Database, practical availability varies significantly across markets. This briefing summarizes the current situation, the clinical implications of the December 2025 generic approval, and actionable guidance for managing patients through this period.

Current Availability Status

As of 2026, Imvexxy (estradiol vaginal inserts, 4 mcg and 10 mcg) is not listed on the FDA's Drug Shortage Database. The product is commercially available through the national distribution network. However, prescribers should be aware of the following practical availability challenges:

• Many independent and smaller retail pharmacies do not routinely stock Imvexxy due to low prescription volume and high product cost
• Medicare Part D plans typically do not cover Imvexxy, limiting its utilization among older postmenopausal patients and reducing pharmacy stocking incentives
• Most commercial formularies place Imvexxy on Tier 3 or higher, requiring prior authorization and sometimes step therapy with generic vaginal estrogen first
• The manufacturer transition from TherapeuticsMD to Mayne Pharma may have affected distributor relationships in some regions, creating sporadic supply gaps

The December 2025 FDA Generic Approval: Clinical Implications

On December 8, 2025, the FDA approved the first generic version of Imvexxy — estradiol vaginal inserts in 4 mcg and 10 mcg strengths. The generic product has been demonstrated to be bioequivalent to Imvexxy under FDA standards, confirming equivalent systemic exposure and the same active ingredient, dosage form, route of administration, and indication.

From a prescribing standpoint, this means:

• Prescriptions written for "Imvexxy" may be automatically substituted with the generic at the pharmacy level in most states (unless DAW-1 is specified)
• Writing prescriptions for "estradiol vaginal inserts 4 mcg" or "estradiol vaginal inserts 10 mcg" (rather than brand) will allow pharmacists to dispense whichever formulation is in stock
• Generic estradiol vaginal inserts are expected to carry lower costs and broader formulary coverage than brand-name Imvexxy

Formulary Considerations and Prior Authorization

When submitting prior authorization requests for Imvexxy, the clinical documentation should clearly articulate:

• The patient's diagnosis of moderate to severe dyspareunia or VVA/GSM due to menopause
• Preference for the 4 mcg dose (if applicable), which is only available in Imvexxy — standard Vagifem and its generic are only 10 mcg
• Any contraindications or intolerances to cream- or ring-based formulations that would justify inserts over alternatives
• For step therapy requirements: document any trials or intolerances to required prior agents

Therapeutically Equivalent Alternatives to Consider

When Imvexxy is unavailable or not covered, the following local estrogen therapies offer comparable efficacy for dyspareunia and VVA/GSM:

• Estradiol vaginal tablets (Vagifem generic / Yuvafem): 10 mcg, inserted with applicator twice weekly. Widely available, generic cost typically $30–$70/month with discount coupons.
• Estradiol vaginal cream (Estrace generic): 0.01%, applied with graduated applicator. Flexible dosing; generic widely available; often lowest cost option at ~$15–$40/month.
• Estradiol vaginal ring (Estring): 2 mg ring replaced every 90 days. High adherence, minimal systemic absorption; brand only.
• Ospemifene (Osphena): 60 mg oral SERM; FDA-approved for dyspareunia and vaginal dryness; appropriate for patients preferring oral administration.

Communicating With Patients About Availability

When patients report difficulty filling their Imvexxy prescription, clinicians can:

1. Inform patients that medfinder.com (a paid prescription locator service) can identify pharmacies near them that currently have Imvexxy in stock
2. Rewrite the prescription as "estradiol vaginal inserts" (generic) to give pharmacists flexibility to dispense whatever is in stock
3. Provide bridge therapy with vaginal estradiol cream while Imvexxy is sourced, if continuity of treatment is time-sensitive
4. Direct patients to the Mayne Pharma savings card program (imvexxy.com/savings-information), which can reduce copays to as low as $35 for commercially insured patients

Resources for Providers

medfinder offers a provider platform that allows prescribers to direct patients to the most effective pharmacy-finding tool available. For a step-by-step guide specifically for providers, see our provider's guide to helping patients find Imvexxy.